375 related articles for article (PubMed ID: 27418644)
1. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
An G; Acharya C; Feng X; Wen K; Zhong M; Zhang L; Munshi NC; Qiu L; Tai YT; Anderson KC
Blood; 2016 Sep; 128(12):1590-603. PubMed ID: 27418644
[TBL] [Abstract][Full Text] [Related]
2. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
3. The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.
Bolzoni M; Toscani D; Costa F; Vicario E; Aversa F; Giuliani N
Immunol Lett; 2019 Jan; 205():65-70. PubMed ID: 29702149
[TBL] [Abstract][Full Text] [Related]
4. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
Tai YT; Lin L; Xing L; Cho SF; Yu T; Acharya C; Wen K; Hsieh PA; Dulos J; van Elsas A; Munshi N; Richardson P; Anderson KC
Leukemia; 2019 Feb; 33(2):426-438. PubMed ID: 30135465
[TBL] [Abstract][Full Text] [Related]
5. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
6. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived mesenchymal stem cells inhibit CD8
Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
9. Human renal tubular epithelial cells suppress alloreactive T cell proliferation.
Demmers MW; Korevaar SS; Roemeling-van Rhijn M; van den Bosch TP; Hoogduijn MJ; Betjes MG; Weimar W; Baan CC; Rowshani AT
Clin Exp Immunol; 2015 Mar; 179(3):509-19. PubMed ID: 25310899
[TBL] [Abstract][Full Text] [Related]
10. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
12. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells.
Li H; Hong S; Qian J; Zheng Y; Yang J; Yi Q
Blood; 2010 Jul; 116(2):210-7. PubMed ID: 20304810
[TBL] [Abstract][Full Text] [Related]
13. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
14. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
15. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
16. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade Reinvigorates Bone Marrow CD8
Kwon M; Kim CG; Lee H; Cho H; Kim Y; Lee EC; Choi SJ; Park J; Seo IH; Bogen B; Song IC; Jo DY; Kim JS; Park SH; Choi I; Choi YS; Shin EC
Clin Cancer Res; 2020 Apr; 26(7):1644-1655. PubMed ID: 31941832
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]